#1 Clinical Trials Search in Europe

Gemtuzumab Ozogamicin

Gemtuzumab Ozogamicin, also known as Mylotarg, is a targeted therapy drug being studied in clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These trials aim to evaluate the safety and effectiveness of Gemtuzumab Ozogamicin alone or in combination with other treatments like chemotherapy or stem cell transplantation. Researchers are investigating its potential to improve outcomes for patients with these challenging blood cancers.

Table of Contents

What is Gemtuzumab Ozogamicin?

Gemtuzumab Ozogamicin, also known by its brand name Mylotarg, is a targeted therapy drug used in the treatment of certain types of blood cancers[1]. It belongs to a class of drugs called antibody-drug conjugates, which combine a targeted antibody with a potent chemotherapy drug[2].

How Does It Work?

Gemtuzumab Ozogamicin works by targeting a specific protein called CD33, which is often found on the surface of leukemia cells[2]. The drug attaches to this protein and delivers a toxic substance directly to the cancer cells, causing them to die. This targeted approach helps to minimize damage to healthy cells, potentially reducing side effects compared to traditional chemotherapy[2].

What Conditions Does It Treat?

Gemtuzumab Ozogamicin is primarily used to treat:

  • Acute Myeloid Leukemia (AML): This is a type of blood cancer where the bone marrow produces abnormal white blood cells[1][3].
  • High-Risk Myelodysplastic Syndrome (MDS): This is a group of disorders where the bone marrow doesn’t produce enough healthy blood cells[2].

It’s important to note that Gemtuzumab Ozogamicin is often used in patients whose cancer has returned after initial treatment (relapsed) or hasn’t responded well to other treatments (refractory)[1].

How is It Administered?

Gemtuzumab Ozogamicin is typically given through an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The dosage and schedule can vary depending on the specific treatment plan, but here’s a general outline:

  • It’s often given in cycles, with each cycle lasting about 4-8 weeks[1].
  • In each cycle, you might receive the drug on days 1, 4, and 7[1].
  • The infusion usually takes about 2 hours[4].
  • Before each infusion, you may receive medications to help prevent allergic reactions and other side effects[2].

Current Clinical Trials

Researchers are continually studying Gemtuzumab Ozogamicin to improve its effectiveness and explore new ways to use it. Some current areas of research include:

  • Combining Gemtuzumab Ozogamicin with other drugs like Decitabine or Venetoclax to potentially enhance its effectiveness[2][5].
  • Using it as part of treatment regimens before or after stem cell transplantation[6][4].
  • Studying its effects on the heart’s electrical activity (QT interval)[1].
  • Investigating its use in newly diagnosed AML patients[7].

Potential Side Effects

Like all medications, Gemtuzumab Ozogamicin can cause side effects. Some potential side effects include:

  • Infusion-related reactions: These can include fever, chills, or low blood pressure during or shortly after the infusion[2].
  • Low blood cell counts: This can increase the risk of infection, bleeding, or anemia[1].
  • Liver problems: In rare cases, a serious condition called veno-occlusive disease can occur[1].
  • Nausea and vomiting[2].

Your healthcare team will monitor you closely for these and other potential side effects throughout your treatment. It’s important to report any new symptoms or changes in your health to your doctor promptly.

Aspect Details
Drug Name Gemtuzumab Ozogamicin (Mylotarg)
Primary Conditions Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Mechanism of Action Targets CD33 protein on leukemia cells, causing cell death
Administration Intravenous infusion, typically 3 mg/m² on specific days of treatment cycle
Common Combinations With chemotherapy (e.g., decitabine), after stem cell transplantation, with venetoclax
Key Outcomes Measured Complete remission rates, overall survival, event-free survival, pharmacokinetics, QT interval changes
Safety Considerations Potential for allergic reactions, nausea, vomiting; premedication often used
Current Status FDA approved for some AML cases; investigational for other uses and combinations

FAQ

  • What is Gemtuzumab Ozogamicin? Gemtuzumab Ozogamicin, also known as Mylotarg, is a targeted therapy drug designed to attach to CD33, a protein often found on leukemia cells. This attachment causes the leukemia cells to die.
  • What types of cancer is Gemtuzumab Ozogamicin being studied for? Gemtuzumab Ozogamicin is primarily being studied for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
  • How is Gemtuzumab Ozogamicin administered in clinical trials? In most trials, Gemtuzumab Ozogamicin is administered intravenously (through a vein) over 1-2 hours. The dosage and frequency vary between studies, but common regimens include 3 mg/m² on days 1, 4, and 7 of a treatment cycle.
  • What are some common side effects of Gemtuzumab Ozogamicin? Common side effects may include allergic reactions, nausea, and vomiting. To help prevent these, patients often receive medications like Benadryl and hydrocortisone before Gemtuzumab Ozogamicin administration.
  • Is Gemtuzumab Ozogamicin approved for use outside of clinical trials? Yes, Gemtuzumab Ozogamicin is FDA approved for the treatment of AML in certain situations, such as for patients over 65 years old with relapsed AML. However, its use in combination with other treatments or for other conditions may still be investigational.

Ongoing Clinical Trials on Gemtuzumab Ozogamicin

  • Venetoclax plus drug combination versus drug combination alone in children with relapsed acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

  • Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Italy The Netherlands Sweden

  • Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Czechia Germany Italy Lithuania Portugal Romania +1

  • Study on Midostaurin and Gemtuzumab Ozogamicin for Adults with Acute Myeloid Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Germany

  • Study on Personalized Treatment for Acute Myeloid Leukemia Using Cladribine, Daunorubicin, Cytarabine, and Drug Combinations for Specific Patient Groups

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Denmark Estonia Finland Iceland Latvia +6

  • Study Comparing Venetoclax and Azacitidine with Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutations Eligible for Intensive Treatment

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • Study comparing venetoclax with intensive chemotherapy (daunorubicin, cytarabine, gemtuzumab ozogamicin) in patients with favorable risk acute myeloid leukemia

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Austria Czechia Germany Greece Italy Poland

Glossary

  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells that interfere with the production of normal blood cells.
  • Myelodysplastic Syndrome (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells, which can lead to problems like anemia and can progress to acute myeloid leukemia in some cases.
  • CD33: A protein often found on the surface of leukemia cells, which is targeted by Gemtuzumab Ozogamicin.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Bone Marrow Aspirate: A procedure to collect a sample of bone marrow fluid and cells to examine for abnormalities or to check the status of blood cell production.
  • Complete Remission (CR): A state where there is no evidence of disease and blood cell counts have returned to normal levels, typically defined as less than 5% blasts in the bone marrow.
  • Minimal Residual Disease (MRD): The small number of cancer cells that may remain in the body during or after treatment, often undetectable by standard tests.
  • Allogeneic Stem Cell Transplantation (AlloSCT): A procedure where a patient receives blood-forming stem cells from a genetically similar, but not identical, donor to replace diseased or damaged bone marrow.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • QT Interval: A measurement on an electrocardiogram that represents the time it takes for the heart's electrical system to fire an impulse and then recharge.

References

  1. https://clinicaltrials.gov/study/NCT03727750
  2. https://clinicaltrials.gov/study/NCT00882102
  3. https://clinicaltrials.gov/study/NCT00909168
  4. https://clinicaltrials.gov/study/NCT02117297
  5. https://clinicaltrials.gov/study/NCT04070768
  6. https://clinicaltrials.gov/study/NCT02221310
  7. https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-gemtuzumab-ozogamicin-with-chemotherapy-in-adults-aged-18-60-with-newly-diagnosed-acute-myeloid-leukemia/